These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 8620671

  • 1. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
    Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, Granneman GR.
    Clin Pharmacokinet; 1995; 29 Suppl 2():49-61. PubMed ID: 8620671
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
    Wong SL, Awni WM, Cavanaugh JH, el-Shourbagy T, Locke CS, Dubé LM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
    [Abstract] [Full Text] [Related]

  • 3. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
    Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavannaugh JH, Awni WM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670
    [Abstract] [Full Text] [Related]

  • 4. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interactions between zileuton and prednisone.
    Awni WM, Cavanaugh JH, Tzeng TB, Witt G, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.
    Awni WM, Wong S, Chu SY, Patterson K, Hansen R, Machinist JM, Drajesk J, Keane WF, Halstenson CE.
    J Clin Pharmacol; 1997 May; 37(5):395-404. PubMed ID: 9156372
    [Abstract] [Full Text] [Related]

  • 7. The effect of food on the pharmacokinetics of zileuton.
    Awni WM, Cavanaugh JH, Witt G, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():62-6. PubMed ID: 8620672
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
    Awni WM, Braeckman RA, Granneman GR, Witt G, Dubé LM.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():22-33. PubMed ID: 8620668
    [Abstract] [Full Text] [Related]

  • 9. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
    Machinist JM, Kukulka MJ, Bopp BA.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():34-41. PubMed ID: 8620669
    [Abstract] [Full Text] [Related]

  • 10. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():112-24. PubMed ID: 8620667
    [Abstract] [Full Text] [Related]

  • 11. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM, Braeckman RA, Locke CS, Dubé LM, Granneman GR.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():98-104. PubMed ID: 8620678
    [Abstract] [Full Text] [Related]

  • 12. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E, Cavanaugh JH, Mukherjee D, Granneman GR.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():84-91. PubMed ID: 8620675
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dubé LM, Cavanaugh JH.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():67-76. PubMed ID: 8620673
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
    Awni WM, Locke C, Dube LM, Cavanaugh JH.
    J Clin Pharmacol; 1997 May; 37(5):388-94. PubMed ID: 9156371
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
    Awni WM, Granneman GR, Locke CS, Brandwein SR, Dube LM.
    Eur J Clin Pharmacol; 1995 May; 48(2):155-60. PubMed ID: 7589031
    [Abstract] [Full Text] [Related]

  • 16. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
    Granneman GR, Braeckman RA, Erdman KA.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():1-8. PubMed ID: 8620665
    [Abstract] [Full Text] [Related]

  • 17. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
    Awni WM, Hussein Z, Cavanaugh JH, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995 May; 29 Suppl 2():92-7. PubMed ID: 8620677
    [Abstract] [Full Text] [Related]

  • 18. The effect of zileuton on antipyrine and indocyanine green disposition.
    St Peter JV, Braeckman RA, Granneman GR, Locke CS, Cavanaugh JH, Awni WM.
    Clin Pharmacol Ther; 1995 Mar; 57(3):299-308. PubMed ID: 7697947
    [Abstract] [Full Text] [Related]

  • 19. Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.
    Macdonald JI, Wallace SM, Mahachai V, Verbeeck RK.
    Eur J Clin Pharmacol; 1992 Mar; 42(5):471-4. PubMed ID: 1606992
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P, Dubé L, Braeckman R, Swanson L, Hansen R, Albert D, Carter G.
    Agents Actions Suppl; 1991 Mar; 35():103-16. PubMed ID: 1781415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.